US Bancorp’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$119M Sell
856,921
-2,150
-0.3% -$301K 0.15% 116
2025
Q4
$105M Buy
859,071
+9,187
+1% +$1.12M 0.12% 129
2025
Q3
$94.3M Sell
849,884
-4,668
-0.5% -$531K 0.11% 136
2025
Q2
$94.7M Sell
854,552
-22,670
-3% -$2.41M 0.12% 135
2025
Q1
$98.3M Sell
877,222
-218,098
-20% -$22.5M 0.13% 127
2024
Q4
$101M Sell
1,095,320
-27,216
-2% -$2.45M 0.13% 129
2024
Q3
$94.1M Sell
1,122,536
-70,772
-6% -$5.4M 0.12% 135
2024
Q2
$81.9M Sell
1,193,308
-194,668
-14% -$13M 0.11% 136
2024
Q1
$102M Sell
1,387,976
-31,356
-2% -$2.41M 0.14% 124
2023
Q4
$115M Sell
1,419,332
-36,531
-3% -$2.84M 0.17% 107
2023
Q3
$110M Sell
1,455,863
-30,111
-2% -$2.32M 0.18% 106
2023
Q2
$115M Sell
1,485,974
-74,881
-5% -$5.97M 0.18% 105
2023
Q1
$130M Sell
1,560,855
-110,046
-7% -$9.11M 0.22% 97
2022
Q4
$143M Buy
1,670,901
+109,507
+7% +$8.67M 0.25% 82
2022
Q3
$96.3M Buy
1,561,394
+4,761
+0.3% +$300K 0.2% 102
2022
Q2
$96.2M Sell
1,556,633
-30,551
-2% -$1.89M 0.19% 111
2022
Q1
$94.4M Sell
1,587,184
-61,353
-4% -$3.92M 0.16% 118
2021
Q4
$120M Buy
1,648,537
+1,499
+0.1% +$103K 0.19% 106
2021
Q3
$115M Buy
1,647,038
+47,456
+3% +$3.33M 0.22% 100
2021
Q2
$110M Buy
1,599,582
+38,191
+2% +$2.55M 0.21% 102
2021
Q1
$101M Buy
1,561,391
+117,679
+8% +$7.59M 0.2% 102
2020
Q4
$84.1M Buy
1,443,712
+84,815
+6% +$5.12M 0.18% 114
2020
Q3
$85.9M Sell
1,358,897
-57,785
-4% -$4.01M 0.21% 101
2020
Q2
$109M Sell
1,416,682
-19,837
-1% -$1.52M 0.29% 79
2020
Q1
$107M Buy
1,436,519
+181,229
+14% +$12.5M 0.34% 72
2019
Q4
$81.6M Buy
1,255,290
+12,388
+1% +$807K 0.21% 103
2019
Q3
$78.8M Buy
1,242,902
+91,724
+8% +$6M 0.21% 104
2019
Q2
$77.8M Buy
1,151,178
+81,548
+8% +$5.36M 0.22% 104
2019
Q1
$69.5M Buy
1,069,630
+10,665
+1% +$709K 0.2% 109
2018
Q4
$66.2M Sell
1,058,965
-34,735
-3% -$2.43M 0.21% 104
2018
Q3
$84.4M Sell
1,093,700
-57,363
-5% -$4.33M 0.24% 99
2018
Q2
$81.5M Sell
1,151,063
-20,009
-2% -$1.41M 0.25% 94
2018
Q1
$88.3M Buy
1,171,072
+52,618
+5% +$4.18M 0.27% 93
2017
Q4
$80.1M Buy
1,118,454
+33,981
+3% +$2.58M 0.25% 100
2017
Q3
$87.9M Buy
1,084,473
+62,434
+6% +$4.77M 0.28% 87
2017
Q2
$72.3M Buy
1,022,039
+144,403
+16% +$9.61M 0.24% 99
2017
Q1
$59.6M Sell
877,636
-46,768
-5% -$3.29M 0.2% 106
2016
Q4
$66.2M Sell
924,404
-50,424
-5% -$3.75M 0.24% 100
2016
Q3
$77.1M Sell
974,828
-40,927
-4% -$3.32M 0.29% 88
2016
Q2
$84.7M Sell
1,015,755
-21,093
-2% -$1.87M 0.32% 80
2016
Q1
$95.2M Sell
1,036,848
-33,705
-3% -$3.04M 0.37% 72
2015
Q4
$108M Sell
1,070,553
-17,073
-2% -$1.78M 0.44% 55
2015
Q3
$107M Sell
1,087,626
-7,636
-0.7% -$848K 0.45% 56
2015
Q2
$128M Sell
1,095,262
-13,917
-1% -$1.52M 0.5% 47
2015
Q1
$109M Buy
1,109,179
+46,423
+4% +$4.71M 0.42% 57
2014
Q4
$100M Buy
1,062,756
+25,367
+2% +$2.62M 0.39% 59
2014
Q3
$110M Buy
1,037,389
+9,906
+1% +$970K 0.45% 53
2014
Q2
$85.2M Buy
1,027,483
+59,044
+6% +$4.6M 0.34% 60
2014
Q1
$68.6M Buy
968,439
+66,004
+7% +$5.18M 0.28% 75
2013
Q4
$67.8M Sell
902,435
-10,587
-1% -$737K 0.27% 78
2013
Q3
$57.4M Buy
913,022
+59,256
+7% +$3.54M 0.25% 87
2013
Q2
$43.8M Buy
+853,766
New +$44.5M 0.2% 104

Other funds holding GILD

US Bancorp's GILD Position: Q1 2026 in Review

US Bancorp reduced its Gilead Sciences (GILD) stake by 0.25% in Q1 2026, selling an estimated $301K and leaving 856,921 shares worth $119M. The position accounts for 0.15% of the portfolio, ranked #116.

US Bancorp first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $143M in Q4 2022. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • US Bancorp held 856,921 shares of Gilead Sciences worth $119M as of Q1 2026.
  • US Bancorp sold 2,150 Gilead Sciences shares in Q1 2026, an estimated $301K.
  • Gilead Sciences made up 0.15% of US Bancorp's portfolio in Q1 2026, its #116 holding.
  • US Bancorp first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • US Bancorp's Gilead Sciences position peaked at $143M in Q4 2022.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.